TB Biosciences Inc. is an early stage development medical diagnostics company founded in June 2013 to develop a rapid point-of-care tuberculosis test that meets performance standards around the world. The goal of TB Biosciences is to commercialize a simple to operate and use tuberculosis test that replaces the 125 year old sputum smear test. The Company is using an array of patented peptides developed and exclusively licensed from the NYU School of Medicine.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/18/13 | $1,500,000 | Series A |
Ben Franklin Technology Partners of Northeastern Pennsylvania NYU Innovation Fund Originate Ventures | undisclosed |
